Enlivex Therapeutics Raises $212 Million, Expands into Crypto Prediction Markets and Advances Osteoarthritis Therapy

Enlivex Therapeutics raised $212 million through a private equity deal and is using part of the funds to build a digital asset treasury via the RAIN token, a decentralized prediction market protocol. The company holds 76 billion RAIN tokens and an option to buy nearly $918 million more at a deep discount. Its osteoarthritis therapy Allocetra continues to show promising results in clinical trials. HC Wainwright reaffirmed a Buy rating on Enlivex and raised its 12-month price target to $13, citing both the RAIN token strategy and clinical progress.